The development of endovascular treatment for intracranial aneurysms has established new techniques such as balloon and stent-assistance, flow diversion and endosaccular occlusion devices. Antiplatelet treatment is an important aspect to reduce risk of thrombus formation on microcatheters and implanted devices when utilizing these methods. It is particularly relevant for flow diverting stents to prevent early and late stent thrombosis. Consideration of platelet physiology and appropriate selection of antiplatelet medication is important as platelet dysfunction drives many of the pathological processes and complications of neurointerventional procedures. Part one of this review focuses on basic platelet physiology, pharmacology of common antiplatelet medications and future directions and therapies. Part two focuses on clinical applications and evidence-based therapeutic regimens.

中文翻译：

---

用于神经干预的抗血小板药物：第1部分临床药理学。

颅内动脉瘤的血管内治疗的发展建立了新技术，例如球囊和支架辅助，血流转移和囊内阻塞装置。使用这些方法时，抗血小板治疗是降低微导管和植入设备上血栓形成风险的重要方面。对于分流支架以防止早期和晚期支架血栓形成尤其重要。考虑血小板生理和抗血小板药物的适当选择的是作为血小板功能驱动器的许多病理过程和神经介入的程序并发症的重要。本综述的第一部分侧重于基本的血小板生理学，常用抗血小板药物的药理学以及未来的方向和疗法。